On May, 8 Penumbra, Inc. (PEN) EPS Estimated At $-0.02

April 16, 2018 - By Michael Higginson

Penumbra, Inc. (NYSE:PEN) Corporate Logo

On May, 8 WallStreet anticipated Penumbra, Inc. (NYSE:PEN)’s earnings report, RTT reports. Analysts have expectation on stock’s EPS of $-0.02. That’s up 80.00 % from last year’s $-0.1 EPS. Analysts at Wall Street see Penumbra, Inc.’s -120.00 % negative EPS growth compared to $0.10 EPS for last quarter. PEN reached $123 on during the last trading session after $0.9 change.Penumbra, Inc. has volume of 124,074 shares. Since April 17, 2017 PEN has risen 41.68% and is uptrending. PEN outperformed by 30.13% the S&P500.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally.The firm is worth $4.20 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand.The P/E ratio is 946.15. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

Penumbra, Inc. (NYSE:PEN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.